Many people thought tuberculosis had gone away. Unfortunately, it has not. Indeed, it is coming back strongly, and in a multidrug resistant form. This has occurred at a time of a vacuum in drug discovery and development for tuberculosis. Fortunately, government institutions like the National Institutes of Health, non-governmental agencies like the Seattle Biomedical Research … Continue reading “TB Isn’t Going Away, and Pharma Isn’t Ignoring It”
Author: Bruce Carter
Bruce Carter is the chairman of Seattle-based ZymoGenetics, and the chairman the Global Alliance for TB Drug Development (TB Alliance). He was appointed ZymoGenetics chairman in April 2005. From April 1998 to January 2009, he served as Chief Executive Officer. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1988 Novo Nordisk acquired ZymoGenetics and, in 1994, Dr. Carter was promoted to Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk A/S, the then parent company of ZymoGenetics. Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.